Treatment of hepatocellular carcinoma during the COVID‐19 outbreak: The Working Group report of JAMTT‐HCC

This contingency guide was formulated on the premise that delivering standard treatment for hepatocellular carcinoma (HCC) has come under strain due to the coronavirus (COVID‐19) pandemic. Measures required are likely to vary largely across regions and individual institutions, depending on the level...

Descripción completa

Detalles Bibliográficos
Autores principales: Kudo, Masatoshi, Kurosaki, Masayuki, Ikeda, Masafumi, Aikata, Hiroshi, Hiraoka, Atsushi, Torimura, Takuji, Sakamoto, Naoya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7361293/
https://www.ncbi.nlm.nih.gov/pubmed/32583525
http://dx.doi.org/10.1111/hepr.13541
_version_ 1783559362110816256
author Kudo, Masatoshi
Kurosaki, Masayuki
Ikeda, Masafumi
Aikata, Hiroshi
Hiraoka, Atsushi
Torimura, Takuji
Sakamoto, Naoya
author_facet Kudo, Masatoshi
Kurosaki, Masayuki
Ikeda, Masafumi
Aikata, Hiroshi
Hiraoka, Atsushi
Torimura, Takuji
Sakamoto, Naoya
author_sort Kudo, Masatoshi
collection PubMed
description This contingency guide was formulated on the premise that delivering standard treatment for hepatocellular carcinoma (HCC) has come under strain due to the coronavirus (COVID‐19) pandemic. Measures required are likely to vary largely across regions and individual institutions, depending on the level of the strain imposed by the pandemic (e.g., number of inpatients infected with COVID‐19 and the availability of resources, including personal protective equipment and inpatient beds). In addition, models suggest that the second and third waves of COVID‐19 will occur before effective vaccines and medicines become widely available in Japan (expected time, 2–3 years). This guide should serve as a good reference for best practices in the management of HCC, which is in light of the possible risk of impending collapse of the healthcare system due to a surge in COVID‐19 infections.
format Online
Article
Text
id pubmed-7361293
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-73612932020-07-15 Treatment of hepatocellular carcinoma during the COVID‐19 outbreak: The Working Group report of JAMTT‐HCC Kudo, Masatoshi Kurosaki, Masayuki Ikeda, Masafumi Aikata, Hiroshi Hiraoka, Atsushi Torimura, Takuji Sakamoto, Naoya Hepatol Res Special Report This contingency guide was formulated on the premise that delivering standard treatment for hepatocellular carcinoma (HCC) has come under strain due to the coronavirus (COVID‐19) pandemic. Measures required are likely to vary largely across regions and individual institutions, depending on the level of the strain imposed by the pandemic (e.g., number of inpatients infected with COVID‐19 and the availability of resources, including personal protective equipment and inpatient beds). In addition, models suggest that the second and third waves of COVID‐19 will occur before effective vaccines and medicines become widely available in Japan (expected time, 2–3 years). This guide should serve as a good reference for best practices in the management of HCC, which is in light of the possible risk of impending collapse of the healthcare system due to a surge in COVID‐19 infections. John Wiley and Sons Inc. 2020-07-20 2020-09 /pmc/articles/PMC7361293/ /pubmed/32583525 http://dx.doi.org/10.1111/hepr.13541 Text en © 2020 The Authors. Hepatology Research published by John Wiley & Sons Australia, Ltd on behalf of Japan Society of Hepatology https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Special Report
Kudo, Masatoshi
Kurosaki, Masayuki
Ikeda, Masafumi
Aikata, Hiroshi
Hiraoka, Atsushi
Torimura, Takuji
Sakamoto, Naoya
Treatment of hepatocellular carcinoma during the COVID‐19 outbreak: The Working Group report of JAMTT‐HCC
title Treatment of hepatocellular carcinoma during the COVID‐19 outbreak: The Working Group report of JAMTT‐HCC
title_full Treatment of hepatocellular carcinoma during the COVID‐19 outbreak: The Working Group report of JAMTT‐HCC
title_fullStr Treatment of hepatocellular carcinoma during the COVID‐19 outbreak: The Working Group report of JAMTT‐HCC
title_full_unstemmed Treatment of hepatocellular carcinoma during the COVID‐19 outbreak: The Working Group report of JAMTT‐HCC
title_short Treatment of hepatocellular carcinoma during the COVID‐19 outbreak: The Working Group report of JAMTT‐HCC
title_sort treatment of hepatocellular carcinoma during the covid‐19 outbreak: the working group report of jamtt‐hcc
topic Special Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7361293/
https://www.ncbi.nlm.nih.gov/pubmed/32583525
http://dx.doi.org/10.1111/hepr.13541
work_keys_str_mv AT kudomasatoshi treatmentofhepatocellularcarcinomaduringthecovid19outbreaktheworkinggroupreportofjamtthcc
AT kurosakimasayuki treatmentofhepatocellularcarcinomaduringthecovid19outbreaktheworkinggroupreportofjamtthcc
AT ikedamasafumi treatmentofhepatocellularcarcinomaduringthecovid19outbreaktheworkinggroupreportofjamtthcc
AT aikatahiroshi treatmentofhepatocellularcarcinomaduringthecovid19outbreaktheworkinggroupreportofjamtthcc
AT hiraokaatsushi treatmentofhepatocellularcarcinomaduringthecovid19outbreaktheworkinggroupreportofjamtthcc
AT torimuratakuji treatmentofhepatocellularcarcinomaduringthecovid19outbreaktheworkinggroupreportofjamtthcc
AT sakamotonaoya treatmentofhepatocellularcarcinomaduringthecovid19outbreaktheworkinggroupreportofjamtthcc